# EMPAGLIFLOZIN REDUCES MORTALITY AND HOSPITALIZATION FOR HEART FAILURE IN PATIENTS WITH OR WITHOUT A HISTORY OF MYOCARDIAL INFARCTION OR STROKE AT BASELINE

**Type:** Papers  
**Canonical URL:** https://scholariq.org/papers/empagliflozin-reduces-mortality-and-hospitalization-for-heart-failure-in/

## Facts

| Field | Value |
| --- | --- |
| Author Names | David Fitchett,Silvio E. Inzucchi,Steven Sambevski,Stefan Kaspers,Egon Pfarr,Jyothis T. George,Bernard Zinman |
| Citations | 3 |
| DOI | 10.1016/s0735-1097(18)32260-5 |
| Fields | Biochemistry, Genetics and Molecular Biology,Medicine |
| Open Access | false |
| OA Status | closed |
| OpenAlex ID | https://openalex.org/W2793465758 |
| Type | article |
| Year | 2018 |

## Paper authors

- [Egon Pfarr](https://scholariq.org/researchers/egon-pfarr/)

## Paper journal

- [Journal of the American College of Cardiology](https://scholariq.org/journals/journal-of-the-american-college-of-cardiology/)

## Paper primary topic

- [Diabetes Treatment and Management](https://scholariq.org/topics/diabetes-treatment-and-management/)

## Paper topics

- [Diabetes Treatment and Management](https://scholariq.org/topics/diabetes-treatment-and-management/)
- [Heart Failure Treatment and Management](https://scholariq.org/topics/heart-failure-treatment-and-management/)
- [Adenosine and Purinergic Signaling](https://scholariq.org/topics/adenosine-and-purinergic-signaling/)

---
Source: ScholarIQ — public research metadata, principally OpenAlex. See https://scholariq.org/sources/ for provenance and https://scholariq.org/methodology/ for what these figures mean.